Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration

Masayuki Tahara,Tomoko Oeda,Kazumasa Okada,Kazuhide Ochi,Hirofumi Maruyama,Hikoaki Fukaura,Kyoichi Nomura,Yuko Shimizu,Ichiro Nakashima,Tatsuro Misu,Atsushi Umemura,Kenji Yamamoto,Hideyuki Sawada

Multiple Sclerosis and Related Disorders（2022）

引用 9|浏览16

暂无评分

摘要

•The RIN-2 study is an open-label extension study following the RIN-1 study.•It revealed the long-term efficacy and safety of RTX in NMOSD patients.•CD-19 and CD-20 lymphocyte monitoring can be a marker of B-cell depletion by RTX.

查看译文

关键词

Neuromyelitis optica spectrum disorders,Rituximab,Clinical trial,Open-label,Aquaporin 4

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要